572 related articles for article (PubMed ID: 26802049)
21. Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation.
Debaize L; Jakobczyk H; Avner S; Gaudichon J; Rio AG; Sérandour AA; Dorsheimer L; Chalmel F; Carroll JS; Zörnig M; Rieger MA; Delalande O; Salbert G; Galibert MD; Gandemer V; Troadec MB
Nucleic Acids Res; 2018 Nov; 46(21):11214-11228. PubMed ID: 30500954
[TBL] [Abstract][Full Text] [Related]
22. An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies.
Wang H; Li W; Guo R; Sun J; Cui J; Wang G; Hoffman AR; Hu JF
Int J Cancer; 2014 Dec; 135(12):2783-94. PubMed ID: 24752773
[TBL] [Abstract][Full Text] [Related]
23. Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
Fasan A; Alpermann T; Haferlach C; Grossmann V; Roller A; Kohlmann A; Eder C; Kern W; Haferlach T; Schnittger S
PLoS One; 2013; 8(2):e54365. PubMed ID: 23383300
[TBL] [Abstract][Full Text] [Related]
24. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
[TBL] [Abstract][Full Text] [Related]
25. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
26. Gatekeeper function of the RUNX1 transcription factor in acute leukemia.
Niebuhr B; Fischer M; Täger M; Cammenga J; Stocking C
Blood Cells Mol Dis; 2008; 40(2):211-8. PubMed ID: 17920312
[TBL] [Abstract][Full Text] [Related]
27. The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.
Bakshi R; Hassan MQ; Pratap J; Lian JB; Montecino MA; van Wijnen AJ; Stein JL; Imbalzano AN; Stein GS
J Cell Physiol; 2010 Nov; 225(2):569-76. PubMed ID: 20506188
[TBL] [Abstract][Full Text] [Related]
28. RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.
Romanova EI; Zubritskiy AV; Lioznova AV; Ogunleye AJ; Golotin VA; Guts AA; Lennartsson A; Demidov ON; Medvedeva YA
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232714
[TBL] [Abstract][Full Text] [Related]
29. RUNX1-ETO Leukemia.
Lin S; Mulloy JC; Goyama S
Adv Exp Med Biol; 2017; 962():151-173. PubMed ID: 28299657
[TBL] [Abstract][Full Text] [Related]
30. ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells.
Redondo Monte E; Wilding A; Leubolt G; Kerbs P; Bagnoli JW; Hartmann L; Hiddemann W; Chen-Wichmann L; Krebs S; Blum H; Cusan M; Vick B; Jeremias I; Enard W; Theurich S; Wichmann C; Greif PA
Oncogene; 2020 Apr; 39(15):3195-3205. PubMed ID: 32115572
[TBL] [Abstract][Full Text] [Related]
31. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
Zhao Y; Zhang T; Zhao Y; Zhou J
Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
[TBL] [Abstract][Full Text] [Related]
32. C/EBPα in normal and malignant myelopoiesis.
Friedman AD
Int J Hematol; 2015 Apr; 101(4):330-41. PubMed ID: 25753223
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
34. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients.
Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Baranowska A; Siedlecki JA
Leuk Res; 2014 Jul; 38(7):850-6. PubMed ID: 24878001
[TBL] [Abstract][Full Text] [Related]
35. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.
Seipel K; Marques MT; Bozzini MA; Meinken C; Mueller BU; Pabst T
Clin Cancer Res; 2016 Feb; 22(3):746-56. PubMed ID: 26408402
[TBL] [Abstract][Full Text] [Related]
37. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
38. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
[TBL] [Abstract][Full Text] [Related]
39. Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.
Maharry SE; Walker CJ; Liyanarachchi S; Mehta S; Patel M; Bainazar MA; Huang X; Lankenau MA; Hoag KW; Ranganathan P; Garzon R; Blachly JS; Guttridge DC; Bloomfield CD; de la Chapelle A; Eisfeld AK
Cancer Discov; 2016 Sep; 6(9):1036-51. PubMed ID: 27354268
[TBL] [Abstract][Full Text] [Related]
40. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
Goryainova NV
Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
